Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF.

Blood Adv. 2019 Nov 26;3(22):3579-3589. doi: 10.1182/bloodadvances.2019000922.

2.

The importance of adequate recognition of normal and dysplastic myelopoiesis for the diagnosis of myelodysplastic syndromes.

Florensa L, Arenillas L, Calvo X, Pérez-Vila E, Montesdeoca S, Ferrer A, Woessner S.

Histol Histopathol. 2019 Aug;34(8):857-873. doi: 10.14670/HH-18-093. Epub 2019 Feb 19. Review.

PMID:
30779051
3.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2.

Riley LG, Heeney MM, Rudinger-Thirion J, Frugier M, Campagna DR, Zhou R, Hale GA, Hilliard LM, Kaplan JA, Kwiatkowski JL, Sieff CA, Steensma DP, Rennings AJ, Simons A, Schaap N, Roodenburg RJ, Kleefstra T, Arenillas L, Fita-Torró J, Ahmed R, Abboud M, Bechara E, Farah R, Tamminga RYJ, Bottomley SS, Sanchez M, Huls G, Swinkels DW, Christodoulou J, Fleming MD.

Haematologica. 2018 Dec;103(12):2008-2015. doi: 10.3324/haematol.2017.182659. Epub 2018 Jul 19.

4.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Recasens-Zorzo C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, Esteve-Arenys A, Clot G, Guerrero-Hernández M, Rodríguez V, Soldini D, Valera A, Moros A, Climent F, González-Barca E, Mercadal S, Arenillas L, Calvo X, Mate JL, Gutiérrez-García G, Casanova I, Mangues R, Sanjuan-Pla A, Bueno C, Menéndez P, Martínez A, Colomer D, Tejedor RE, Teixidó J, Campo E, López-Guillermo A, Borrell JI, Colomo L, Pérez-Galán P, Roué G.

Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.

5.

Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes.

Alvarez-Larran A, Martínez D, Arenillas L, Rubio A, Arellano-Rodrigo E, Hernández Boluda JC, Papaleo N, Caballero G, Martínez C, Ferrer-Marín F, Mata MI, Pérez-Encinas M, Durán MA, Alonso JM, Carreño-Tarragona G, Alonso JM, Noya S, Magro E, Pérez R, López-Guerra M, Pastor-Galán I, Cervantes F, Besses C, Colomo L, Rozman M.

J Clin Pathol. 2018 Nov;71(11):975-980. doi: 10.1136/jclinpath-2018-205227. Epub 2018 Jun 22.

PMID:
29934356
6.

(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes.

Calvo X, Florensa L, Arenillas L.

Leukemia. 2018 May;32(5):1264-1266. doi: 10.1038/s41375-018-0064-6. Epub 2018 Feb 22. No abstract available.

PMID:
29483710
7.

Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?

Calvo X, Florensa L, Arenillas L.

Leukemia. 2017 Jul 31. doi: 10.1038/leu.2017.237. [Epub ahead of print]

PMID:
28757616
8.

Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.

Ramos F, Robledo C, Pereira A, Pedro C, Benito R, de Paz R, Del Rey M, Insunza A, Tormo M, Díez-Campelo M, Xicoy B, Salido E, Sánchez-Del-Real J, Arenillas L, Florensa L, Luño E, Del Cañizo C, Sanz GF, María Hernández-Rivas J; Spanish Group for Myelodysplastic Syndromes (GESMD).

Am J Hematol. 2017 Sep;92(9):E534-E541. doi: 10.1002/ajh.24813. Epub 2017 Jul 19.

9.

Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L.

Am J Hematol. 2017 Jul;92(7):614-621. doi: 10.1002/ajh.24732. Epub 2017 May 9.

10.

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.

Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM, Teixidó M, Gimenez MT, Senín A, Sanz P, Campoy D, Vicent A, Arenillas L, Rosiñol L, Sierra J, Bladé J, de Larrea CF; GEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya).

Haematologica. 2017 Jun;102(6):1099-1104. doi: 10.3324/haematol.2016.158303. Epub 2017 Mar 2.

11.

Reply to M.A. Lichtman.

Arenillas L, Calvo X, Sanz GF, Florensa L.

J Clin Oncol. 2017 Apr 20;35(12):1376-1377. doi: 10.1200/JCO.2016.71.3941. Epub 2017 Jan 30. No abstract available.

PMID:
28135144
12.

Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L.

Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26.

13.

Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.

Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L.

J Clin Oncol. 2016 Sep 20;34(27):3284-92. doi: 10.1200/JCO.2016.66.9705. Epub 2016 Jul 5.

PMID:
27382099
14.

Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?

Saumell S, Solé F, Arenillas L, Montoro J, Valcárcel D, Pedro C, Sanzo C, Luño E, Giménez T, Arnan M, Pomares H, De Paz R, Arrizabalaga B, Jerez A, Martínez AB, Sánchez-Castro J, Rodríguez-Gambarte JD, Raya JM, Ríos E, Rodríguez-Rivera M, Espinet B, Florensa L.

PLoS One. 2015 Jun 12;10(6):e0129375. doi: 10.1371/journal.pone.0129375. eCollection 2015.

15.

Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes.

Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, García-Cerecedo T, López R, Talavera E, Fernández-Ruiz S, Ademà V, Marugan I, Luño E, Sanzo C, Vallespí T, Arenillas L, Marco Buades J, Batlle A, Buño I, Martín Ramos ML, Blázquez Rios B, Collado Nieto R, Vargas MT, González Martínez T, Sanz G, Solé F; Spanish Group for Mds Study (GESMD); Spanish Group for Clinical Cytogenetics (Gcecgh).

Leuk Lymphoma. 2015;56(11):3183-8. doi: 10.3109/10428194.2015.1028053. Epub 2015 May 12.

PMID:
25754580
16.

Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.

Adema V, Larráyoz MJ, Calasanz MJ, Palomo L, Patiño-García A, Agirre X, Hernández-Rivas JM, Lumbreras E, Buño I, Martinez-Laperche C, Mallo M, García O, Álvarez S, Blazquez B, Cervera J, Luño E, Valiente A, Vallespí MT, Arenillas L, Collado R, Pérez-Oteyza J, Solé F.

Br J Haematol. 2015 Oct;171(1):137-41. doi: 10.1111/bjh.13355. Epub 2015 Feb 25. No abstract available.

PMID:
25716545
17.

[Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].

Senín A, Arenillas L, Martínez-Avilés L, Fernández-Rodríguez C, Bellosillo B, Florensa L, Besses C, Álvarez-Larrán A.

Med Clin (Barc). 2015 Jun 8;144(11):487-90. doi: 10.1016/j.medcli.2014.03.020. Epub 2014 May 20. Spanish.

PMID:
24854193
18.

Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.

Rozman M, Navarro JT, Arenillas L, Aventín A, Giménez T, Alonso E, Perea G, Camós M, Navarrete M, Tuset E, Florensa L, Millá F, Nomdedéu J, de la Banda E, Díaz-Beyá M, Pratcorona M, Garrido A, Navarro B, Brunet S, Sierra J, Esteve J; Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas).

Ann Hematol. 2014 Oct;93(10):1695-703. doi: 10.1007/s00277-014-2100-6. Epub 2014 May 14.

PMID:
24824767
19.

Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.

Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C, Puigdecanet E, Gimeno J, Garcia-Garcia M, Vela MC, Luño E, Collado R, Navarro JT, de la Banda E, Abrisqueta P, Arenillas L, Serrano C, Lloreta J, Miñana B, Cerutti A, Florensa L, Orfao A, Sanz F, Solé F, Dominguez-Sola D, Serrano S.

Clin Cancer Res. 2014 Feb 15;20(4):1007-19. doi: 10.1158/1078-0432.CCR-13-1077. Epub 2013 Dec 18.

20.

Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.

Arenillas L, Mallo M, Ramos F, Guinta K, Barragán E, Lumbreras E, Larráyoz MJ, De Paz R, Tormo M, Abáigar M, Pedro C, Cervera J, Such E, José Calasanz M, Díez-Campelo M, Sanz GF, Hernández JM, Luño E, Saumell S, Maciejewski J, Florensa L, Solé F.

Genes Chromosomes Cancer. 2013 Dec;52(12):1167-77. doi: 10.1002/gcc.22112. Epub 2013 Oct 7.

PMID:
24123380
21.

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Espinosa I, Novelli S, Briones J, Mate JL, Salamero O, Sancho JM, Arenillas L, Serrano S, Erill N, Martínez D, Castillo P, Rovira J, Martínez A, Campo E, Colomo L; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB).

Haematologica. 2013 Oct;98(10):1554-62. doi: 10.3324/haematol.2013.086173. Epub 2013 May 28.

22.

Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.

Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, Arenillas L, Valcarcel D, Vallespí T, Costa D, Nomdedeu B, Jimenez MJ, Granada I, Grau J, Ardanaz MT, de la Serna J, Carbonell F, Cervera J, Sierra A, Luño E, Cervero CJ, Falantes J, Calasanz MJ, González-Porrás JR, Bailén A, Amigo ML, Sanz G, Solé F.

Leuk Res. 2013 Jul;37(7):769-76. doi: 10.1016/j.leukres.2013.04.010. Epub 2013 Apr 29.

PMID:
23639672
23.

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F.

Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.

PMID:
23614682
24.

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G.

Blood. 2013 Apr 11;121(15):3005-15. doi: 10.1182/blood-2012-08-452938. Epub 2013 Jan 31.

PMID:
23372164
25.

Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?

Ademà V, Hernández JM, Abáigar M, Lumbreras E, Such E, Calull A, Dominguez E, Arenillas L, Mallo M, Cervera J, Marugán I, Tormo M, García F, González T, Luño E, Sanzo C, Martín ML, Fernández M, Costa D, Blázquez B, Barreña B, Marco F, Batlle A, Buño I, Martínez-Laperche C, Noriega V, Collado R, Ivars D, Carbonell F, Vallcorba I, Melero J, Delgado E, Vargas MT, Grau J, Salido M, Espinet B, Melero C, Florensa L, Pedro C, Solé F.

Leuk Res. 2013 Apr;37(4):416-21. doi: 10.1016/j.leukres.2012.12.010. Epub 2013 Jan 18.

PMID:
23337401
26.

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.

Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L.

Haematologica. 2013 Apr;98(4):568-75. doi: 10.3324/haematol.2012.071449. Epub 2012 Oct 12.

27.

Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes.

Saumell S, Florensa L, Luño E, Sanzo C, Cañizo C, Hernández JM, Cervera J, Gallart MA, Carbonell F, Collado R, Arenillas L, Pedro C, Bargay J, Nomdedeu B, Xicoy B, Vallespí T, Raya JM, Belloch L, Sanz GF, Solé F.

Br J Haematol. 2012 Nov;159(3):311-21. doi: 10.1111/bjh.12035. Epub 2012 Sep 7.

PMID:
22958186
28.

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, Lippert E, Cermak J, Evans J, Mounier M, Raya JM, Bailly F, Gattermann N, Haferlach T, Garand R, Allou K, Besses C, Germing U, Haferlach C, Travaglino E, Luno E, Pinan MA, Arenillas L, Rozman M, Perez Sirvent ML, Favre B, Guy J, Alonso E, Ahwij N, Jerez A, Hermouet S, Maynadié M, Cazzola M, Girodon F.

Haematologica. 2012 Jul;97(7):1036-41. doi: 10.3324/haematol.2011.053918. Epub 2012 Apr 24.

29.

Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array.

Villa O, Mallo M, Kosyakova N, Salido M, Liehr T, Martínez-Avilés L, Pedro C, García-Aragonés M, Espinet B, Bellosillo B, Florensa L, Arenillas L, Cuscó I, Jurado LA, Solé F.

Leuk Res. 2011 Sep;35(9):e161-3. doi: 10.1016/j.leukres.2011.05.027. Epub 2011 Jun 17. No abstract available.

PMID:
21684005
30.

High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.

Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, González-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Braziel R, Rosenwald A, Lenz G, Wright G, Jaffe ES, Staudt L, Jares P, López-Guillermo A, Campo E.

Haematologica. 2011 Jul;96(7):996-1001. doi: 10.3324/haematol.2010.037408. Epub 2011 May 5.

31.

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, Sancho JM, Arenillas L, Serrano S, Escoda L, Martínez S, Valera A, Martínez A, Jares P, Pinyol M, García-Herrera A, Martínez-Trillos A, Giné E, Villamor N, Campo E, Colomo L, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB).

Blood. 2011 May 5;117(18):4836-43. doi: 10.1182/blood-2010-12-322362. Epub 2011 Mar 25.

PMID:
21441466
32.

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.

Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F.

Leukemia. 2011 Jan;25(1):110-20. doi: 10.1038/leu.2010.231. Epub 2010 Sep 30.

PMID:
20882045
33.

TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study.

Mallo M, Osca G, Solórzano J, Arenillas L, Florensa L, Solé F.

Haematologica. 2010 Oct;95(10):1798-800. doi: 10.3324/haematol.2010.027920. Epub 2010 Jun 30. No abstract available.

34.

Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.

Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A.

Leuk Lymphoma. 2010 Jul;51(7):1225-32. doi: 10.3109/10428194.2010.483301.

PMID:
20497002
35.

Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?

Galván AB, Mallo M, Arenillas L, Salido M, Espinet B, Pedro C, Florensa L, Serrano S, Solé F.

Leuk Res. 2010 Sep;34(9):1242-5. doi: 10.1016/j.leukres.2010.03.022. Epub 2010 Apr 1.

PMID:
20362335
36.

Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.

Raya JM, Arenillas L, Domingo A, Bellosillo B, Gutiérrez G, Luño E, Piñán MA, Barbón M, Pérez-Sirvent ML, Muruzábal MJ, Yánez L, García L, Lemes A, Navarro JT, Elosegi A, Cortés MA, Villegas A, Durán MA, Ardanaz M, Florensa L; Grupo Español de Citología Hematológica (GECH), Working Group into the Asociación Española de Hematología y Hemoterapia (AEHH).

Int J Hematol. 2008 Nov;88(4):387-395. doi: 10.1007/s12185-008-0169-1. Epub 2008 Sep 27.

PMID:
18820995
37.

Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia.

Villa O, Salido M, Pérez-Vila ME, Ferrer A, Arenillas L, Pedro C, Espinet B, Corzo C, Serrano S, Woessner S, Florensa L, Solé F.

Cancer Genet Cytogenet. 2008 Aug;185(1):32-6. doi: 10.1016/j.cancergencyto.2008.04.014.

PMID:
18656691
38.

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.

Mallo M, Arenillas L, Espinet B, Salido M, Hernández JM, Lumbreras E, del Rey M, Arranz E, Ramiro S, Font P, González O, Renedo M, Cervera J, Such E, Sanz GF, Luño E, Sanzo C, González M, Calasanz MJ, Mayans J, García-Ballesteros C, Amigo V, Collado R, Oliver I, Carbonell F, Bureo E, Insunza A, Yañez L, Muruzabal MJ, Gómez-Beltrán E, Andreu R, León P, Gómez V, Sanz A, Casasola N, Moreno E, Alegre A, Martín ML, Pedro C, Serrano S, Florensa L, Solé F.

Haematologica. 2008 Jul;93(7):1001-8. doi: 10.3324/haematol.13012.

39.

Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia.

Puigdecanet E, Espinet B, Lozano JJ, Sumoy L, Bellosillo B, Arenillas L, Alvarez-Larrán A, Solé F, Serrano S, Besses C, Florensa L.

Leukemia. 2008 Jul;22(7):1368-76. doi: 10.1038/leu.2008.112. Epub 2008 May 15.

PMID:
18480837
40.

Autologous stem cell transplantation for patients with active Hodgkin's lymphoma: long-term outcome of 61 patients from a single institution.

Martínez C, Salamero O, Arenillas L, Duque J, López-Guillermo A, Rovira M, Urbano-Ispízua A, Fernández-Avilés F, Carreras E, Montserrat E.

Leuk Lymphoma. 2007 Oct;48(10):1968-75.

PMID:
17917965
41.

Bortezomib-induced rhabdomyolysis in multiple myeloma.

Cibeira MT, Mercadal S, Arenillas L, Muntañola A, Salamero O, Bladé J.

Acta Haematol. 2006;116(3):203-6.

PMID:
17016040
42.

The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma.

Giné E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López-Guillermo A.

Ann Oncol. 2006 Oct;17(10):1539-45. Epub 2006 Aug 28.

43.

Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.

Plancarte F, López-Guillermo A, Arenillas L, Montoto S, Giné E, Muntañola A, Ferrer A, Villamor N, Bosch F, Colomo L, Balaguer O, Campo E, Montserrat E.

Eur J Haematol. 2006 Jan;76(1):58-63.

PMID:
16343272
44.

Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.

López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L, Muntañola A, Montoto S, Giné E, Colomer D, Beà S, Campo E, Montserrat E.

J Clin Oncol. 2005 Apr 20;23(12):2797-804. Epub 2005 Feb 22.

PMID:
15728226
45.

Response to thalidomide in multiple myeloma: impact of angiogenic factors.

Rosiñol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M, Rozman M, Arenillas L, Esteve J, Bladé J, Montserrat E.

Cytokine. 2004 May 21;26(4):145-8.

PMID:
15149630
46.

The possibility of a natural cure for death.

Arenillas L.

Med Hypotheses. 1989 Oct;30(2):83-5.

PMID:
2811718
48.

Flurazepam ('Dalmane') in the treatment of insomnia in patients with respiratory disorders.

Pines A, Rooney JF, Arenillas L.

Practitioner. 1976 Aug;217(1298):281-4.

PMID:
9636
49.

Mental subnormality: clinical types, early detection and prevention.

Arenillas L.

Dist Nurs. 1970 Mar;12(12):242-4. No abstract available.

PMID:
5198807
50.

AMITRIPTYLINE AND BODY-WEIGHT.

ARENILLAS L.

Lancet. 1964 Feb 22;1(7330):432-3. No abstract available.

PMID:
14092968

Supplemental Content

Loading ...
Support Center